- Home
- All Stock List
- NSE
- Nectar Lifescience Ltd Share Price
22.95
-0.66 (-2.80%)
-
Underperforms Index
-23.88%
Return (1Y)
Underperformed Nifty 50 by 29.22%
-
More Volatile
3.61%
Standard Deviation (1Y)
Higher than Nifty 50 by 2.72%
-
Inconsistent Performer
3/12
Months
underperformed Nifty 50
-
AxisDirect View
No View
56

22
News & Announcements
-
Nectar Lifesciences slumps after Mohali unit gets seven observations from EU authorities
20 days ago
Nectar Lifesciences slumps after Mohali unit gets seven observations from EU authorities
11 - Mar - 2025 12:00 | 20 days ago
In a regulatory filing made after market hours yesterday, the company stated that its API manufacturing facility in Saidpura, Mohali, Punjab, underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS) to assess compliance with EuGMP standards.
Following the inspection, seven observations including four critical, were noted.
Nectar Lifesciences said that it is in the process of preparing a corrective action and preventive action (CAPA) report to address the observations. The company emphasized its commitment to quality and compliance with cGMP standards.
The European regulator will conduct a re-inspection of the facility to verify the compliance and CAPA submitted which may lead to EuGMP approval.
Nectar Lifesciences is a research-based pharmaceutical company, primarily engaged in manufacturing APIs and formulation. The company has four manufacturing facilities across Punjab and Himachal Pradesh. The company is into manufacturing Cephalosporin (oral and sterile) at its two units in Derabassi and Punjab.
The company's consolidated net profit surged to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in Q3 FY25 as compared with Q3 FY24.
Powered by Capital Market - Live News
-
Nectar Lifescience consolidated net profit rises 399.36% in the December 2024 quarter
01 - Feb - 2025 12:00 | 58 days ago
Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 454.33 452.16 0 OPM % 9.84 9.33 - PBDT 28.16 17.83 58 PBT 12.55 2.46 410 NP 7.84 1.57 399 Powered by Capital Market - Live News
-
Nectar Lifescience announces board meeting date
66 days ago
-
Nectar Lifescience consolidated net profit rises 399.36% in the December 2024 quarter
01 - Feb - 2025 12:00 | 58 days ago
Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 454.33 452.16 0 OPM % 9.84 9.33 - PBDT 28.16 17.83 58 PBT 12.55 2.46 410 NP 7.84 1.57 399 Powered by Capital Market - Live News
-
Nectar Lifescience announces board meeting date
66 days ago
-
Nectar Lifescience consolidated net profit rises 449.02% in the September 2024 quarter
14 - Nov - 2024 12:00 | 137 days ago
Net profit of Nectar Lifescience rose 449.02% to Rs 5.60 crore in the quarter ended September 2024 as against Rs 1.02 crore during the previous quarter ended September 2023. Sales rose 7.52% to Rs 427.88 crore in the quarter ended September 2024 as against Rs 397.96 crore during the previous quarter ended September 2023.
Particulars Quarter Ended Sep. 2024 Sep. 2023 % Var. Sales 427.88 397.96 8 OPM % 10.13 6.75 - PBDT 24.21 16.95 43 PBT 8.67 1.64 429 NP 5.60 1.02 449 Powered by Capital Market - Live News
-
Nectar Lifesciences slumps after Mohali unit gets seven observations from EU authorities
20 days ago
Nectar Lifesciences slumps after Mohali unit gets seven observations from EU authorities
11 - Mar - 2025 12:00 | 20 days ago
In a regulatory filing made after market hours yesterday, the company stated that its API manufacturing facility in Saidpura, Mohali, Punjab, underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS) to assess compliance with EuGMP standards.
Following the inspection, seven observations including four critical, were noted.
Nectar Lifesciences said that it is in the process of preparing a corrective action and preventive action (CAPA) report to address the observations. The company emphasized its commitment to quality and compliance with cGMP standards.
The European regulator will conduct a re-inspection of the facility to verify the compliance and CAPA submitted which may lead to EuGMP approval.
Nectar Lifesciences is a research-based pharmaceutical company, primarily engaged in manufacturing APIs and formulation. The company has four manufacturing facilities across Punjab and Himachal Pradesh. The company is into manufacturing Cephalosporin (oral and sterile) at its two units in Derabassi and Punjab.
The company's consolidated net profit surged to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in Q3 FY25 as compared with Q3 FY24.
Powered by Capital Market - Live News
-
Nectar Lifescience consolidated net profit rises 399.36% in the December 2024 quarter
01 - Feb - 2025 12:00 | 58 days ago
Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 454.33 452.16 0 OPM % 9.84 9.33 - PBDT 28.16 17.83 58 PBT 12.55 2.46 410 NP 7.84 1.57 399 Powered by Capital Market - Live News
-
Nectar Lifescience announces board meeting date
66 days ago
-
Nectar Lifescience consolidated net profit rises 449.02% in the September 2024 quarter
14 - Nov - 2024 12:00 | 137 days ago
Net profit of Nectar Lifescience rose 449.02% to Rs 5.60 crore in the quarter ended September 2024 as against Rs 1.02 crore during the previous quarter ended September 2023. Sales rose 7.52% to Rs 427.88 crore in the quarter ended September 2024 as against Rs 397.96 crore during the previous quarter ended September 2023.
Particulars Quarter Ended Sep. 2024 Sep. 2023 % Var. Sales 427.88 397.96 8 OPM % 10.13 6.75 - PBDT 24.21 16.95 43 PBT 8.67 1.64 429 NP 5.60 1.02 449 Powered by Capital Market - Live News
-
Nectar Lifesciences slumps after Mohali unit gets seven observations from EU authorities
20 days ago
Nectar Lifesciences slumps after Mohali unit gets seven observations from EU authorities
11 - Mar - 2025 12:00 | 20 days ago
In a regulatory filing made after market hours yesterday, the company stated that its API manufacturing facility in Saidpura, Mohali, Punjab, underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS) to assess compliance with EuGMP standards.
Following the inspection, seven observations including four critical, were noted.
Nectar Lifesciences said that it is in the process of preparing a corrective action and preventive action (CAPA) report to address the observations. The company emphasized its commitment to quality and compliance with cGMP standards.
The European regulator will conduct a re-inspection of the facility to verify the compliance and CAPA submitted which may lead to EuGMP approval.
Nectar Lifesciences is a research-based pharmaceutical company, primarily engaged in manufacturing APIs and formulation. The company has four manufacturing facilities across Punjab and Himachal Pradesh. The company is into manufacturing Cephalosporin (oral and sterile) at its two units in Derabassi and Punjab.
The company's consolidated net profit surged to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in Q3 FY25 as compared with Q3 FY24.
Powered by Capital Market - Live News
-
Nectar Lifescience consolidated net profit rises 399.36% in the December 2024 quarter
01 - Feb - 2025 12:00 | 58 days ago
Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 454.33 452.16 0 OPM % 9.84 9.33 - PBDT 28.16 17.83 58 PBT 12.55 2.46 410 NP 7.84 1.57 399 Powered by Capital Market - Live News
-
Nectar Lifescience announces board meeting date
66 days ago
-
Nectar Lifescience consolidated net profit rises 399.36% in the December 2024 quarter
01 - Feb - 2025 12:00 | 58 days ago
Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 454.33 452.16 0 OPM % 9.84 9.33 - PBDT 28.16 17.83 58 PBT 12.55 2.46 410 NP 7.84 1.57 399 Powered by Capital Market - Live News
-
Nectar Lifescience announces board meeting date
66 days ago
-
Nectar Lifescience consolidated net profit rises 449.02% in the September 2024 quarter
14 - Nov - 2024 12:00 | 137 days ago
Net profit of Nectar Lifescience rose 449.02% to Rs 5.60 crore in the quarter ended September 2024 as against Rs 1.02 crore during the previous quarter ended September 2023. Sales rose 7.52% to Rs 427.88 crore in the quarter ended September 2024 as against Rs 397.96 crore during the previous quarter ended September 2023.
Particulars Quarter Ended Sep. 2024 Sep. 2023 % Var. Sales 427.88 397.96 8 OPM % 10.13 6.75 - PBDT 24.21 16.95 43 PBT 8.67 1.64 429 NP 5.60 1.02 449 Powered by Capital Market - Live News
Stock Trivia
Nectar Lifescience Ltd is trading very close to its 52 Week Low
FII shareholding in Nectar Lifescience Ltd has decreased by -39.74% since past 1 Year
Nectar Lifescience Ltd is trading very close to its 52 Week Low
FII shareholding in Nectar Lifescience Ltd has decreased by -71.56% since past 3 Months
FII shareholding in Nectar Lifescience Ltd has decreased by -39.74% since past 1 Year
Nectar Lifescience Ltd is trading very close to its 52 Week Low
FII shareholding in Nectar Lifescience Ltd has decreased by -39.74% since past 1 Year
